Breast Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
For all participants:
- People who are willing and able to give written consent to take part
- People aged 18 or older
For people with metastatic breast cancer:
- Women aged 18 or older with a confirmed diagnosis of breast cancer (confirmed through tissue testing)
- People who have at least one area of cancer that has spread to a part of the body other than the bones
- People whose cancer has been assessed by their doctor as getting worse despite their most recent treatment
- People for whom a biopsy (tissue sample), if recommended by their oncologist, is planned to happen within 4 weeks of the blood sample being taken for the study
- People whose last biopsy or minor surgical procedure took place at least 7 days before the blood sample is taken
- People with a known bilirubin level (a liver-related blood measurement) of 2 mg/dL or higher, based on a blood test done within 7 days of joining — if this result is not available, it does not need to be tested (confirm with trial site)
For healthy volunteers:
- People of any sex aged 18 or older who are visiting the trial site for a reason unrelated to a cancer diagnosis (including breast cancer)
Who may not be able to join:
- People who currently have an infection that requires antibiotic or antiviral medication
- People with a history of a blood cancer, or a cancer other than breast cancer that was not treated with the aim of a cure at least 3 years ago, or that has come back since — non-melanoma skin cancer is an exception; for healthy volunteers, a history of breast cancer is also included in this exclusion
- People who have had major surgery within 4 weeks before the blood sample is collected
- People who have started a new course of cancer treatment after their disease got worse, at the time of blood or tissue collection
- People with a known serious blood clotting or blood disorder
- People who are pregnant
- For people with metastatic breast cancer: people whose breast cancer has been confirmed as Triple Negative Breast Cancer (TNBC)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Luca Mazzarella, MD, IEO Hospital
Phone: +39 0294375111
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Evaluation of White Blood Cells adhered on SBS slides; SBS slides stability; cfDNA quality control; Feasibility of using See.d SBS slides for subsequent analysis; Feasibility of using See.d plasma for subsequent analysis
Can't join this trial?
Data last synced from ClinicalTrials.gov: 16 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.